MANCUSO, Salvatrice
 Distribuzione geografica
Continente #
NA - Nord America 9.565
EU - Europa 4.322
AS - Asia 4.173
SA - Sud America 640
AF - Africa 102
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 7
Totale 18.818
Nazione #
US - Stati Uniti d'America 9.416
SG - Singapore 1.558
RU - Federazione Russa 1.211
CN - Cina 1.024
IT - Italia 991
BR - Brasile 494
DE - Germania 449
HK - Hong Kong 419
FI - Finlandia 361
VN - Vietnam 350
PL - Polonia 257
UA - Ucraina 227
GB - Regno Unito 172
JP - Giappone 172
FR - Francia 171
BD - Bangladesh 140
IE - Irlanda 130
SE - Svezia 114
IN - India 112
KR - Corea 81
CA - Canada 69
NL - Olanda 57
AR - Argentina 47
IQ - Iraq 47
TR - Turchia 43
MX - Messico 39
RO - Romania 33
ES - Italia 31
PK - Pakistan 29
AT - Austria 28
IR - Iran 27
ID - Indonesia 24
ZA - Sudafrica 24
BE - Belgio 23
UZ - Uzbekistan 22
VE - Venezuela 22
SA - Arabia Saudita 20
CO - Colombia 19
UY - Uruguay 16
CH - Svizzera 14
EC - Ecuador 14
MA - Marocco 14
CI - Costa d'Avorio 13
CL - Cile 13
JO - Giordania 13
EG - Egitto 12
MY - Malesia 12
CZ - Repubblica Ceca 11
NP - Nepal 11
JM - Giamaica 10
KE - Kenya 10
IL - Israele 9
PH - Filippine 9
PY - Paraguay 9
BG - Bulgaria 8
CR - Costa Rica 8
DZ - Algeria 7
EU - Europa 7
GR - Grecia 7
LT - Lituania 7
AU - Australia 6
KZ - Kazakistan 6
TN - Tunisia 6
AE - Emirati Arabi Uniti 5
AL - Albania 5
LB - Libano 5
AZ - Azerbaigian 4
BB - Barbados 4
BH - Bahrain 4
BO - Bolivia 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
KG - Kirghizistan 4
OM - Oman 4
AO - Angola 3
DK - Danimarca 3
GH - Ghana 3
HN - Honduras 3
HR - Croazia 3
KW - Kuwait 3
PT - Portogallo 3
SI - Slovenia 3
SY - Repubblica araba siriana 3
CY - Cipro 2
GT - Guatemala 2
MM - Myanmar 2
NI - Nicaragua 2
PA - Panama 2
PR - Porto Rico 2
SR - Suriname 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
BF - Burkina Faso 1
BN - Brunei Darussalam 1
BW - Botswana 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
GE - Georgia 1
GP - Guadalupe 1
HU - Ungheria 1
Totale 18.805
Città #
Ashburn 1.155
Fairfield 1.076
Singapore 979
Chandler 532
San Jose 522
Woodbridge 500
Houston 491
Wilmington 441
Hong Kong 404
Seattle 385
Cambridge 363
Secaucus 338
Ann Arbor 269
Zgierz 228
Beijing 211
Moscow 194
Council Bluffs 184
Palermo 164
Medford 160
Des Moines 153
Tokyo 151
Helsinki 146
Los Angeles 131
Dublin 129
Dallas 126
Santa Clara 125
Ho Chi Minh City 108
New York 107
Nanjing 106
Lauterbourg 104
Altamura 103
Princeton 103
Frankfurt am Main 102
Jacksonville 95
Hanoi 89
The Dalles 82
Dearborn 81
Hefei 81
Boardman 80
Lawrence 75
Buffalo 74
Rome 68
San Diego 65
Milan 64
Chicago 49
São Paulo 45
Tulsa 42
Ludwigshafen am Rhein 39
Columbus 37
Shenyang 36
Amsterdam 30
London 29
Orem 29
Hebei 28
Atlanta 27
Nanchang 27
Seoul 27
Tianjin 27
Phoenix 24
Brooklyn 23
Brussels 23
Changsha 22
Jinan 22
Ningbo 22
Chennai 21
Jiaxing 21
Guangzhou 20
Tashkent 19
Nuremberg 18
Piscataway 18
Zhengzhou 18
Baghdad 17
Poplar 17
Venice 17
Warsaw 17
Da Nang 16
Denver 16
Rio de Janeiro 16
Toronto 16
Bremen 15
San Paolo di Civitate 15
Tehran 15
Kumar 14
Lappeenranta 14
Redwood City 14
Washington 14
Abidjan 13
Curitiba 13
Hangzhou 13
Montreal 13
Haiphong 12
Montevideo 12
Mumbai 12
Saint Petersburg 12
Shanghai 12
Stockholm 12
Amman 11
Johannesburg 11
Vienna 11
Biên Hòa 9
Totale 12.286
Nome #
Absolute Lymphocyte Count Is Unrelated to Overall Survival in Newly Diagnosed Elderly Patients with Multiple Myeloma Treated with Immunomodulatory Drugs. 489
Copanlisib in combination with rituximab and bendamustine for transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma patients: Results from the phase II multicentre FIL Copa-BR trial from Fondazione Italiana Linfomi (FIL) 449
Clinical phenotype and response to different lines of therapy in elderly with immune thrombocytopenia: A retrospective study 327
Comparison between thrombotic risk scores in Essential Thrombocythemia and survival implications 304
Cardiovascular risk in polycythemia vera: Thrombotic risk and survival: Can cytoreductive therapy be useful in patients with low-risk polycythemia vera with cardiovascular risk factors? 278
Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system 272
Optimal Duration of Low Molecular Weight Heparin for the Treatment of Cancer-Related Deep Vein Thrombosis: The Cancer-DACUS Study. 259
Acquired haemophilia in cancer: A systematic and critical literature review 258
Buffy coat-derived platelets cryopreserved using a new method: Results from a pivotal clinical trial on thrombocytopenic patients with acute leukaemia 252
Acquired Hemophilia A Associated with Venous Thrombosis and Very High Inhibitor Titer: A Challenging Scenario 234
Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical hodgkin lymphoma and correlation with early FDG-PET assessment 232
T Cell Large Granular Lymphocytic Leukemia in Association with Sjógren's Syndrome 228
Combined Point of Care Tools Are Able to Improve Treatment Adherence and Health-Related Quality of Life in Patients with Severe Hemophilia: An Observational Prospective Study 227
Buffy coat-derived platelets cryopreserved using a new method: Results from in vitro studies 218
Antimicorbial prophylaxis in patients with immune thrombocytopenia treated with rituximab:a retrospective analysis 216
Immunosenescence and lymphomagenesis 214
CARDIOVASCULAR RISK IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THROMBOTIC RISK AND SURVIVAL 212
Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate 212
A Case of Fatal Drug Rash Eosinophilia and Systemic Symptoms from Allopurinol 211
Synthesis and induction of G0-G1 phase arrest with apoptosis of 3,5-dimethyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazepin-4(3H)-one 205
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study 203
Screening sierologico per l'infantum in soggetti HIV+ in area endemica Sicilia occidentale 202
Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study. 202
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: A Fondazione Italiana Linfomi phase II study 201
COMPARISON OF CLINICAL AND LABORATORY DATA, INCLUDING JAK-2 46/1 HAPLOTYPE, BETWEEN PATIENTS WITH IDIOPATHIC ERYTHROCYTOSIS AND POLYCYTHEMIA VERA. 199
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi 198
Screening sierologico per Leishmania infantum su donatori di sangue e HIV+ asintomatici residenti in area endemica [Serological screening for Leishmania infantum in asymptomatic blood donors and HIV+ patients living in an endemic area] 196
Evaluation of Bone Marrow CD8+ tissue-Resident Memory T Cells in Multiple Myeloma 195
Cardio-oncology in multiple myeloma: is it time for a specific focus? 192
Comprehensive Geriatric Assessment is an essential tool to support treatment decisions in elderly patients with Diffuse Large B Cell Lymphoma: A prospective multicenter evaluation on 173 patients by the Lymphoma Italian Foundation (FIL) 190
DETECTION OF HIV TYPE 1 (HIV-1) NON-B SUBTYPES IN SICILY, ITALY 189
Genetic diversity of HIV-1 non-B strains in Sicily: Evidence of intersubtype recombinants by Sequence Analysis of gag, pol, and env genes 186
A novel methodology for large-scale phylogeny partition 185
JAK2 ALLELE BURDEN IN PATIENTS WITH PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS 185
Clinical history of thrombosis before diagnosis of overt myeloproliferative neoplasms in triple negative patients 184
Cardiovascular risk factor in MPN patients 184
ABSOLUTE LYMPHOCYTE COUNT IS NOT A PREDICTOR FOR SURVIVAL IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA. FINAL RESULTS OF A MULTICENTER STUDY 178
PNEUMOCYSTIS JIROVECI PNEUMONIA IN HEMATOLOGICAL PATIENTS: A SINGLE INSTITUTION EXPERIENCE 177
BENDAMUSTINE (B) IN COMBINATION WITH RITUXIMAB (R) FOR PATIENTS WITH RELAPSED/RESISTANT CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): AN ITALIAN MULTICENTRE RETROSPECTIVE STUDY 177
The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors 175
The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep 175
Coexistence of Von Willebrand disease and gastrointestinal stromal tumor (G.I.S.T): Case report of a rare and challenge association 172
Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART 171
A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen 171
"Long term anticoagulant treatment management in patients with portal vein thrombosis at high bleeding risk" 168
ABSOLUTE LYMPHOCYTE COUNT AS PREDICTOR FOR SURVIVAL IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA 166
Management of Ponatinib in Patients with Chronic Myeloid Leukemia with Cardiovascular Risk Factors 165
Isolated Nodal TBC Reactivation in a Patient with Post-Thrombocythemia Myelofibrosis Treated with Ruxolitinib: Case Report and Review of the Literature 165
MESENCHYMAL STEM CELLS IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS: IDLE OBSERVERS OR PART OF THE DISEASE? 164
Lymphomas and thyroid: Bridging the gap 163
CD200 ANTIGEN IN B-CELL DERIVED NEOPLASMS: EXPRESSION AND CLINICAL IMPACT IN 77 CONSECUTIVE PATIENTS OF A SINGLE ISTITUTION 158
EBF1, MYO6 and CALR expression levels predict therapeutic response in diffuse large B-cell lymphomas 157
BENDAMUSTINE IN ASSOCIATION WITH RITUXIMAB AS SALVAGE THERAPY FOR SPLENIC MARGINAL ZONE LYMPHOMA 157
The difference of free light chains as a predictor of kidney damage in patients with Multiple Myeloma 157
ABSOLUTE LYMPHOCYTE COUNT IS NOT A PREDICTOR FOR SURVIVAL IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA 155
Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction 154
CANCER AS A PREDICTOR FOR INCREASED PERIPROCEDURAL BLEEDING DURING SURGERY OR PLATELET-INDUCED CHEMOTHERAPY IN CHRONICALLY ANTICOAGULATED PATIENTS 152
Synthesis and induction of G0-G1 phase arrest with apoptosis of 3,5-dimethyl-6-phenyl-8-trifluoromethyl-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazepin-4-one 151
Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL). 151
Thrombotic complications in paroxysmal nocturnal haemoglobinuria: a literature review. 150
Chronic myeloid leukemia as second malignancy; a retrospective multicentrico study 148
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting 148
Lymphonodal amyloidosis: case report 147
Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials 146
INFEZIONE DA HIV E IMMIGRATI NEGLI ULTIMI CINQUE ANNI DI ATTIVITA' DEL NOSTRO CENTRO 146
Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review 144
Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: A cross-sectional analysis 143
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010 143
Thrombotic risk in paroxysmal nocturnal hemoglobinuria-like (PNH-like) phenotype 142
Host-related factors and cancer: Malnutrition and non-Hodgkin lymphoma 142
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration 140
Recent acquired STD and the use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): Analysis of the incidence of newly acquired hepatitis B infection and syphilis 139
Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different? 138
“Evidence of HIV-1 second-generation recombinant strains (SGRs) in Sicily: sequence analysis of gag, pol, and env genes.” 138
PREDICTORS OF RESIDUAL VEIN THROMBOSIS AFTER CANCER-RELATED DEEP VEIN THROMBOSIS OF THE LOWER LIMBS 137
Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice 136
MOLECULAR EPIDEMIOLOGY OF HIV TYPE 1 (HIV-1) NON-B SUBTYPES IN SICILY 135
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI 134
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort 133
Bone damage after chemotherapy for lymphoma: a real-world experience 133
Dimagrimento e diarrea: oltre la "wasting syndrome" 132
Paroxysmal nocturnal hemoglobinuria-like phenotype and thrombotic risk in several clinical disorders 132
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study 132
AIDS AND SURGICAL PATIENTS 131
E' la pneumocistosi ancora presente in pazienti HIV positivi in epoca HAART? 131
Bendamustin in association with Rituximab (BR) in the treatment of patients with relapsed/refractory lymphoid neoplasm. A GISL retrospective study 129
Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients 128
Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe 126
Paroxysmal nocturnal haemoglobinuria: When delay in diagnosis and long therapy occurs 125
Chronic myeloid leukemia as second malignancy; restrospective multicentric study 123
Functional In Vitro Studies Of Buffy Coat Pooled Platelets Cryopreserved In Dimethyl-Sulphoxide With a New System 123
High Output Heart Failure in Multiple Myeloma: Pathogenetic Considerations 122
No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy 121
Effects of B-Cell Lymphoma on the Immune System and Immune Recovery after Treatment: The Paradigm of Targeted Therapy 121
Nutritional factors and survival in a cohort of patients with myelofibrosis 118
Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: Not All AIDS-defining conditions are created equal 118
Familial essential thrombocythemia: 6 cases from a mono‐institutional series 118
Triple-Negativity Identifies a Subgroup of Patients with Better Overall Survival in Essential Thrombocythemia 118
Molecular epidemiology of HIV type 1 (HIV-1) non-B subtypes in SIcily 115
RICERCA DI GIARDIA, CRYPTOSPORIDIUM E ISOSPORA IN SOGGETTI HIV POSITIVI 114
Totale 17.606
Categoria #
all - tutte 65.524
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.524


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.204 102 222 28 49 19 57 63 68 139 187 73 197
2022/20231.597 155 299 29 164 172 259 107 127 183 27 48 27
2023/2024737 29 103 61 103 55 139 76 24 6 19 18 104
2024/20251.916 57 96 74 177 92 58 132 149 154 208 268 451
2025/20267.877 552 655 372 534 735 1.045 1.094 756 630 859 297 348
2026/2027205 205 0 0 0 0 0 0 0 0 0 0 0
Totale 19.371